Professor Georgina Long named as one of world's most highly cited researchers
4 December 2018
Melanoma Institute Australia’s Co-Medical Director Professor Georgina Long has been included in the 2018 Clarivate Analytics Highly Cited Researchers List in recognition of her global leadership in melanoma research and clinical trials.
Professor Long is one of only 12 researchers from The University of Sydney to be listed in the top one percent of researchers in their field. Professor Long was named in the Clinical Medicine category for her extensive work in melanoma research and clinical trials.
‘This is an outstanding achievement and great recognition of the global impact of Professor Long’s research, particularly in clinical trials,’ said fellow MIA Co-Medical Director Professor Richard Scolyer. ‘We are exceptionally proud to have someone of Georgina’s calibre as part of our team which is changing the face of melanoma treatment around the world.’
Now in its 5th year, the Clarivate Analytics Highly Cited Researchers List names the most influential researchers impacting their chosen fields, measured by rate of citation by their peers. Other researchers on the list include one of this year’s Nobel Laureates in Physiology or Medicine, Professor James P. Allison.
The Academic Ranking of World Universities uses the Highly Cited Researchers List to calculate the Highly Cited Score, which contributes to an institutions overall rank. This year, The University of Sydney climbed 15 places to its highest rank so far, due in no small part to research output of Professor Long and the other 11 researchers.
Melanoma impacts more Australian teenagers and young adults than any other cancer. Dr James Wilmott, who has a young family of his own, has devoted his career to determining why these young Australians are susceptible to melanoma, and importantly, how to save them.
Melanoma Masterclass celebrates Australian luminaries who have transformed melanoma treatment worldwide
The extraordinary contribution of Australia’s most distinguished melanoma clinicians and researchers is being celebrated today.
Congratulations to Professor Richard Scolyer who was awarded the William O. Russell/Joanne Vandenberge Hill Award of Excellence in Pathology.
A Day in the Life Of... Serigne Lo, Research and BioStatistics Manager at Melanoma Institute Australia
Jay was your typical Aussie bloke – a truck driver, husband, dad and mate to many. Then he got melanoma. His cancer diagnosis turned his life upside down.
Clair faced an impossible choice – risk delivering her baby early, or delay potentially life-saving melanoma treatment
Little Madi misses her Dad. But she is determined to honour his memory and support life-saving melanoma research.
Toyota and country music fans invited to tip their hat to help tackle Australia's national cancer – melanoma
Melanoma Institute Australia has teamed up with the Toyota Country Music Festival 2018 in Tamworth!
MIA's dermatologist shares her knowledge with GPs on debunking myths and controversies on sunscreen.
Shannan Ponton thought he was invincible – he wasn’t. But his melanoma battle ended up saving more than his own life.
Researchers have demonstrated that immunotherapy is highly effective in treating a rare form of melanoma – a result that is surprising due to the nature of the tumour.
Innovation is helping to prevent melanoma developing in the first place.
Research from MIA is changing the way melanoma is managed worldwide and improving patient survival. Here are a few of our key highlights from this year.
A prestigious Fellowship has been awarded to fund research that will change the way melanoma treatment is assessed in the future.
New research from MIA has been published that forms the basis of the updated international guidelines for staging melanoma.
Professor William McCarthy AM has been awarded the Tom Reeve Award for Outstanding Contributions to Cancer Care.
Leading researchers from MIA have been acknowledged with three prestigious awards for excellence in melanoma research.
New research shows that patients who are more likely to respond to immunotherapy treatment have a greater diversity in their gut bacteria.
2018 will be bigger than ever, and a little bit different.
MIA's epidemiologist explains her new research on how country of residence should be considered when identifying melanoma risk.